中国医科大学学报

中国医科大学学报

中国医科大学学报 ›› 2012, Vol. 41 ›› Issue (4): 325–328.

• 临床医学 • 上一篇    下一篇

保罗样激酶1蛋白在肝细胞癌中的表达及临床意义

孙威,陈爱山,殷红专,尹剑桥,闫兆鹏,刘宝林   

  1. (中国医科大学附属盛京医院结直肠、肛门病外科,沈阳 110004)
  • 收稿日期:2012-09-24 修回日期:2012-09-24 出版日期:2012-04-20 发布日期:2012-09-26

Expression and Clinical Significance of Plk1 Protein in Hepatocellular Carcinoma

Wei SunUN Wei, Ai-Shan ChenHEN Ai-shan, YIN Hong-Zzhuan Yin,Jian-Qiao YinYIN Jian-qiao,Zhao-Pen YanYAN Zhao-peng, Bao-Lin LiuIU Bao-lin   

  1. (Department of Colonrectalanal Surgery, Shengjing Hospital, China Medical University, Shenyang 110004, China)
  • Received:2012-09-24 Revised:2012-09-24 Online:2012-04-20 Published:2012-09-26

摘要: 目的 探讨肝细胞癌(HCC)组织及细胞系中保罗样激酶1(Plk1)蛋白的表达情况及其临床意义。方法 应用免疫组化SP法检测HCC组织67例、配对癌旁肝硬化组织27例及正常肝组织5例中Plk1蛋白的表达情况,并分析其与临床病理特征之间的关系。应用Western blot检测肝癌细胞系BCL-7402及HepG2细胞中Plk1蛋白的表达情况。结果 Plk1蛋白在HCC肝癌组织中的阳性表达率为76.1%(5167),其中强阳性44.8%(3067),在配对的癌旁肝硬化组织中均呈阳性表达,而5例正常肝组织中均无明显表达。高分化HCC肝癌中Plk1蛋白的表达明显高于中低分化HCC 肝癌(P0.01);无包膜侵犯的HCC肝癌组织中Plk1蛋白的表达高于有包膜侵犯的HCC肝癌组织(P0.05);Plk1的表达与患者年龄、肿瘤直径、肿瘤数目、淋巴结转移、肝外转移、及门静脉有无癌栓无关。肝癌细胞系BCL-7402及HepG2中均存在Plk1蛋白的过表达。结论 Plk1在HCC肝细胞癌中表达率较高,其阳性表达可能是HCC发生过程中一个关键的早期因素。

关键词: 关键词 肝细胞癌, 病理学, 细胞培养, 保罗样激酶1

Abstract: Abstract Objective To investigate the expression and clinical significance of Polo-like kinase 1 (Plk1) protein in hepatocellular carcinoma (HCC) tissues and the expression of Plk1 protein in hepatocellular carcinoma cell lines. Methods Immunohistochemical technique (SP) was used to detect the expression of the Plk1 gene protein in HCC tissues of 67 cases ofcases HCC tissues, 27 cases of corresponding paracancerous cirrhosis tissues and 5 cases of normal tissues of liver. And tThe relationship between clinical pathology characters and expression of the Plk1 protein were analyzed as well. Western Blot was used to detect the expression of the Plk1 protein in hepatocellular carcinoma cell lines BCL-7402 and HepG2. Results: The positive rates of Plk1 in HCC tissues was were 76.1% and 44.8% of all carcinomas showed strong expression of Plk1. 27 Twenty-seven cases of corresponding paracancerous cirrhosis tissues all showed positive expression. No significant Plk1 expression was observed in normal tissues of liver. The expression of Plk1 protein in well differentiation differentiated HCC tissues was markedly higher than that of poor differentiation tissues (P0.01). In addition, HCC tissues with peplos encroachment showed lower expression rates than that of others without peplos encroachment (P0.05). There was were no other significant correlations of Plk1 expression with either age, tumor diameter and numberquantity, lymphoid node metastasis, extrahepatic metastasis, or portal vein embolus could be established. Plk1 protein was found to be overexpressed in both hepatocellular carcinoma cell lines. Conclusions:These results demonstrated a higher rate of Plk1-positivity in HCC which suggested involvement of Plk1 in tumorigenesis in this tumor entity and might be an important early event of this process. Therefore, targeted strategies focussing on Plk1 inhibition might represent a promising new therapy approach in hepatocellular carcinoma.

Key words: hepatocellular carcinoma, pathology, cell culture

中图分类号: 

  • R73 文献标志码 A 文章编号
[1] Fode C, Motro B, Yousefi S, et al. A murine protein-serinethreonine kinase that is related to the Drosophila polo kinase and involved in cell proliferation[J]. Proc Natl Acad Sci U S A,1994,91(14) 6388-6392.
[2] Bahassi el M. . Polo-like kinases and DNA damage checkpoint beyond the traditional mitotic functions[J]. Exp Biol Med (Maywood), 2011,236(6) 648-657.
[3] Li B, Ouyang B, Pan H, et al.A cytokine- inducible human protein serinethreonine kinase whose expression appears to be down-regulated in lung carcinomas[J].J Biol Chem,1996,271(32)19402-19408.
[4] Smits VA, Klompmaker R, Arnaud L, et al. Polo-like kinase-1 is a target of the DNA damage checkpoint[J]. Nat Cell Biol, 2000,2(9)672-676.
[5] Studach L, Wang WH, Weber G, et al. Polo-like kinase 1 activated by the hepatitis B virus X protein attenuates both the DNA damage checkpoint and DNA repair resulting in partial polyploidy[J].J Biol Chem,2010, 285(39)30282-30293.
[6] Hamanaka R, Smith MR, O'Connor PM, et al. Polo-like kinase is a cell cycle-regulated kinase activated during mitosis[J]. J Biol Chem,1995, 270(36)21086-21091.
[7] Jiang PD, Zhao YL, Shi W, et al. Cell growth inhibition, G2M cell cycle arrest, and apoptosis induced by chloroquine in human breast cancer cell line Bcap-37[J]. Cell Physiol Biochem,2008,22(5-6)431-440.
[8] Degenhardt Y, Lampkin T. Targeting Polo-like kinase in cancer therapy[J]. Clin Cancer Res,2010,16(2)384-389.
[9] Clay FJ, McEwen SJ, Bertoncello I, et al. Identification and cloning of a protein kinase-encoding mouse gene, Plk, related to the polo gene of Drosophila[J]. Proc Natl Acad Sci USA,1993,90(11) 4882-4886.
[10] Lake RJ, Jelinek WR. Cell cycle- and terminal differentiation-associated regulation of the mouse mRNA encoding a conserved mitotic protein kinase[J]. Mol Cell Biol,1993,13(12)7793-7801.
[11] Petronczki M, L閚醨t P, Peters JM.Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1[J]. Dev Cell,2008,14(5)646-659.
[12] Zhou Q, Su Y, Bai M. Effect of antisense RNA targeting Polo-like kinase 1 on cell growth in A549 lung cancer cells[J].J Huazhong Univ Sci Technolog Med Sci,2008,28(1)22-26.
[13] Feng YB, Lin DC, Shi ZZ, et al. Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma[J]. Int J Cancer,2009,, 124(3)578-588.
[14] Steinhauser I, Langer K, Strebhardt K, et al. Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression[J]. J Drug Target,2009,17(8)627-637.
[15] R?del F, Keppner S, Capalbo G, et al. Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer[J]. Am J Pathol,2010,177(2)918-929.
[16] Jimeno A, Rubio-Viqueira B, Rajeshkumar NV, et al. A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer[J]. Mol Cancer Ther,2010,9(2)311-318.
[17] Salvatore G, Nappi TC, Salerno P, et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma[J]. Cancer Res,2007,67(21)10148-10158.
[18] Shi W, Alajez NM, Bastianutto C, et al. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer[J]. Int J Cancer,2010, 126(9)2036-2048.
[19] Chhavi, Saxena M, Singh S, et al.Expression profiling of G2M phase regulatory proteins in normal, premalignant and malignant uterine cervix and their correlation with survival of patients[J]. J Cancer Res Ther,2010 , 6(2) 167-171.
[20] Wang XQ, Zhu YQ, Lui KS, et al. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma[J]. Clin Cancer Res, 2008,14(21)6813-6820.
[21] Reagan-Shaw S, Ahmad N.Polo-like kinase (Plk) 1 as a target for prostate cancer management[J].IUBMB Life,2005,57(10)677-682.
[1] 郑吉龙, 倪首涛, 章彪, 霍德民, 赵开放, 刘夏, 杨森. 家兔失血性休克死后肝脏CT影像学变化与死亡时间的关系[J]. 中国医科大学学报, 2018, 47(3): 212-216.
[2] 富聪聪,夏禹,王传卓,李飞,孟帆,黄玮,潘诗农. 肾上皮样血管平滑肌脂肪瘤的CT和超声表现与病理对照分析[J]. 中国医科大学学报, 2014, 43(8): 752-755.
[3] 张岩,王雪飞,徐枫,那飞,赵巍. 骨桥蛋白与基质金属蛋白酶9在子宫内膜病变中的表达[J]. 中国医科大学学报, 2013, 42(1): 49-51.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!

中国医科大学学报版权所有©2018

未经允许,严禁擅自转载本站图文资料

地址:中国 沈阳市沈北新区蒲河路77号 110122

辽ICP备05014850

JOURNAL OF CHINA MEDICAL UNIVERSITY

ADDRESS: NO.77 PUHE ROAD

SHENYANG NORTH NEW AREA, SHENYANG

LIAONING PROVINCE, P.R. CHINA